TMC125-C227: A PHASE II RANDOMIZED, ACTIVE-CONTROLLED, OPEN LABEL TRIAL TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF TMC125 IN HIV-1 INFECTED SUBJECTS, WHO ARE PI-NAIVE AND WITH DOCUMENTED GENOTYPIC EVIDENCE OF NNRTI RESISTANCE FROM PREVIOUS NNRTI USE: